Tariffs have always been part of clinical trials. Whenever supplies, equipment, or study materials cross borders, duties and fees are part of the process. For years, these costs were predictable enough to be absorbed into budgets and timelines. Sponsors and CROs planned accordingly, and study teams treated the impact of tariffs on clinical research as a background factor that rarely disrupted study timelines.<\/p>\n
That changed in 2025. Reciprocal tariffs<\/a> (duties that mirror those imposed by another country) entered the conversation and quickly became a reality. Governments responded to trade disputes by imposing duties that mirrored those of their counterparts. \u00a0The impact of tariffs on clinical trials was immediate<\/a> and exponential. Materials that once moved relatively freely became more expensive overnight. Customs officials applied new rules, slowing clearance for clinical trial supplies. Study teams found themselves adjusting budgets and schedules midstream, often while trials were already underway. What had long been a manageable detail became a source of uncertainty.<\/p>\n The effects were felt across the research ecosystem. Sponsors faced higher costs and CROs had to rework logistics to keep sites supplied on time. Tariffs were no longer background noise; they were shaping the rhythm of global research.<\/p>\n As of late 2025, about 60% of registered clinical trials involve sites outside the U.S.,<\/a> making them global in scope. For organizations conducting trials in another country, tariffs add friction to already complex operations. While no single tactic eliminates the challenge, several approaches help study teams maintain control:<\/p>\n These measures do not erase the impact of tariffs in clinical research, but they give study teams tools to manage uncertainty with greater confidence.<\/p>\n Several developments could shape the global clinical trial environment in the months ahead. Tariffs may escalate further, adding pressure to already strained supply chains. Negotiated relief or exemptions for pharmaceuticals and medical devices could stabilize budgets.<\/p>\n Sponsors may also invest in diversified sourcing<\/a>, building redundancy into supply chains to reduce exposure to sudden policy shifts. Industry voices are seeing the same trend:<\/p>\n Tariffs have actually accelerated the industry\u2019s focus toward what the U.S. should have prioritized decades ago, building more resilient, domestically centered supply chains that reduce long-term risk.\u201d<\/p>\nPractical Approaches for Clinical Trials<\/h2>\n
\n
What to Watch in 2026<\/h2>\n
\n